ConductScience.org, home

Paper6889461

Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer.

Schilsky RL and 2 others. Cancer Treat Rep, 1982. Cited by 98 papers, by iCite.

Cite this record

ConductScience Library. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Papers, record 6889461. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6889461

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1982
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
98
iCite
Relative citation ratio, by iCite
4.58
iCite
Revised in PubMed
2013-11-21
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schilsky RLR L
2Barlock AA
3Ozols RFR F

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CisplatinMajor topic
Magnesium DeficiencyMajor topic
Testicular NeoplasmsMajor topic
Dysgerminoma
Follow-Up Studies
Humans
Magnesium
Male
Muscles

Source PubMed

Download CSV of topics

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 98 citations.

PMIDTitleJournalYearIn PapersSource
41938717Hypomagnesemia Associated with Omeprazole Use in Patients Treated with Platinum Derivatives: An Exploratory Randomized Placebo-Controlled Clinical Trial.Can J Hosp Pharm2026https://conductscience.org/library/papers/41938717PubMed
41854743Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity: A Mechanistic Review.Kidney3602026https://conductscience.org/library/papers/41854743PubMed
34278747An overview of diagnosis and management of drug-induced hypomagnesemia.Pharmacol Res Perspect2021https://conductscience.org/library/papers/34278747PubMed
28758697Renal toxicity and chemotherapy in children with cancer.Br J Clin Pharmacol2017https://conductscience.org/library/papers/28758697PubMed
27281266Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.Am J Clin Oncol2018https://conductscience.org/library/papers/27281266PubMed
27057522Effect of Oral Magnesium Oxide Supplementation on Cisplatin-Induced Hypomagnesemia in Cancer Patients: A Randomized Controlled Trial.Iran J Public Health2016https://conductscience.org/library/papers/27057522PubMed
24278698Membrane transporters as mediators of Cisplatin effects and side effects.Scientifica (Cairo)2012https://conductscience.org/library/papers/24278698PubMed
21505757Does cisplatin-based chemotherapy effect on blood lipid levels of patients with germ cell testicular tumor in long-term follow-up?Int Urol Nephrol2011https://conductscience.org/library/papers/21505757PubMed
19629622Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats.Clin Exp Nephrol2009https://conductscience.org/library/papers/19629622PubMed
17848741Long-term complications of platinum-based chemotherapy in testicular cancer survivors.Med Oncol2007https://conductscience.org/library/papers/17848741PubMed
16205699The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area.Br J Cancer2005https://conductscience.org/library/papers/16205699PubMed
16119971Drug-induced hypomagnesaemia : scope and management.Drug Saf2005https://conductscience.org/library/papers/16119971PubMed
9635848Cisplatin dose rate as a risk factor for nephrotoxicity in children.Br J Cancer1998https://conductscience.org/library/papers/9635848PubMed
8980410Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.Br J Cancer1996https://conductscience.org/library/papers/8980410PubMed
8573296Comparative adverse effect profiles of platinum drugs.Drug Saf1995https://conductscience.org/library/papers/8573296PubMed
7807572Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II.J Natl Med Assoc1994https://conductscience.org/library/papers/7807572PubMed
3918779A clinical approach to common electrolyte problems: 4. Hypomagnesemia.Can Med Assoc J1985https://conductscience.org/library/papers/3918779PubMed
3524645Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial.Br J Cancer1986https://conductscience.org/library/papers/3524645PubMed
2875808Cumulative renal tubular damage associated with cisplatin nephrotoxicity.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/2875808PubMed
2731311Does parenteral magnesium sulfate have an antiemetic effect during chemotherapy with cis-platinum?Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2731311PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6889461

GET https://conductscience.org/api/papers/v1/6889461/cited_by?page=2